Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 35-07 (SOLE) 

A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node-positive early stage breast cancer.

Study Of Letrozole Extension (SOLE)

DESIGN

please click on the picture to see a larger version

Results & Publications


Presentations

Study Chairs
Dr. Marco Colleoni - Milano, Italy

Statisticians
Prof. Richard Gelber
Dr. Meredith Regan

Trial Coordinators
Mary Caporale, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg35_SOLE@fstrf.org

Date of Activation
November 8, 2007

Targeted Accrual
4800 patients

Results Publications Results & Publications
Other Pathology


News

11.12.2008:
BIG 1-98: Results from sequential treatment analysis and updated monotherapy analysis

11.12.2008:
Brinker Award for Richard Gelber and Aron Goldhirsch

11.12.2008:
All presentations from investigators' meetings at San Antonio Breast Cancer Symposium now

All News

 
  Print